Sandbox Reserved 1167: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 7: Line 7:


== Background ==
== Background ==
[[Image:7tm_labeled_with_membrane.png|200 px|left|thumb|The 7tm spans the cell membrane]]
[[Image:7tm_labeled_with_membrane.png|200 px|left|thumb|The 7tm spans the cell membrane]]The human glucagon receptor (GCGR) is one of 15 secretin-like, or Class B, G-protein-coupled receptors (GPCRs). Like other GPCRs, it has a <scene name='72/721538/7tm_labeled_helicies/3'>7 trans-membrane </scene> helical domain (shown in blue) and a globular N-terminus <scene name='72/721538/Ecd/2'>extracellular domain</scene> (shown in magenta). As its name suggests, the 7tm is made up of alpha helices that pass through the membrane seven times. The extracellular domain has an α-β-β structure that consists of two antiparallel β-sheets and a N-terminal α-helix<ref>PMID:26227798</ref>.  
The human glucagon receptor (GCGR) is one of 15 secretin-like, or Class B, G-protein-coupled receptors (GPCRs). Like other GPCRs, it has a <scene name='72/721538/7tm_labeled_helicies/3'>7 trans-membrane </scene> helical domain (shown in blue) and a globular N-terminus <scene name='72/721538/Ecd/2'>extracellular domain</scene> (shown in magenta). As its name suggests, the 7tm is made up of alpha helices that pass through the membrane seven times. The extracellular domain has an α-β-β structure that consists of two antiparallel β-sheets and a N-terminal α-helix<ref>PMID:26227798</ref>.  




Line 56: Line 55:
== Clinical Relevance ==
== Clinical Relevance ==


Because of GCGRs role in glucose homeostasis, it is a potential drug target for Type 2 diabetes. Specifically, molecules that antagoinze the glucagon receptor may be able to lower blood sugar levels.  
Because of GCGR's role in glucose homeostasis, it is a potential drug target for Type 2 diabetes. Specifically, molecules that antagoinze the glucagon receptor may be able to lower blood sugar levels. Studies have shown that two antibodies, mAb1 and mAb23, target the ECD domain of the GCGR interrupt glucagon binding<ref>PMID:22908259</ref>. Disrupting the normal interactions between the ECD and the 7tm domains, these antibiotics inhibit the receptor's function and help to lower blood glucose level. Additional research has shown that another antibody, mAb7, inhibits GCGR allosterically<ref>PMID:24189067</ref>. Binding to a site outside of the binding pocket, mAb7 inhibits the receptor without interacting with essential glucagon binding residues.  


</StructureSection>
</StructureSection>

Revision as of 04:22, 30 March 2016

This Sandbox is Reserved from Jan 11 through August 12, 2016 for use in the course CH462 Central Metabolism taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1160 through Sandbox Reserved 1184.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Class B Human Glucagon G-Protein Coupled Receptor

Human Glucagon Class B GPCR ( 7tm PDB: 4l6r, ECD PDB: 4ers)

Drag the structure with the mouse to rotate

References